DDInter1008 DDInter1229
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue
Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significant antimuscarinic activity, which is responsible both for the therapeutic effects of these medications and their broad range of adverse effects. Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its use alongside solifenacin in refractory cases. Mirabegron first received FDA approval in 2012, under the brand name Myrbetriq, for the treatment of adults with overactive bladder. An extended-release granule formulation was subsequently granted approval in March 2021 for the treatment of pediatric patients with neurogenic detrusor overactivity. Mirabegron is also used in other jurisdictions across the globe, including Canada, the EU, and Japan.
Ketoconazole {u} (Compound) binds {v} (Gene) SLCO1A2
SLCO1A2 {u} (Gene) is bound by {v} (Compound) Mirabegron
Ketoconazole {u} (Compound) causes {v} (Side Effect) Urticaria
Urticaria {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Ketoconazole {u} (Compound) binds {v} (Gene) SLCO1A2
SLCO1A2 {u} (Gene) is bound by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Ketoconazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Propafenone
Propafenone {u} (Compound) resembles {v} (Compound) Mirabegron
Ketoconazole {u} (Compound) causes {v} (Side Effect) Urticaria
Urticaria {u} (Side Effect) is caused by {v} (Compound) Propafenone
Propafenone {u} (Compound) resembles {v} (Compound) Mirabegron
Ketoconazole {u} (Compound) causes {v} (Side Effect) Erythema multiforme
Erythema multiforme {u} (Side Effect) is caused by {v} (Compound) Aprepitant
Aprepitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Ketoconazole {u} (Compound) causes {v} (Side Effect) Arthralgia
Arthralgia {u} (Side Effect) is caused by {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Ketoconazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Ketoconazole {u} (Compound) causes {v} (Side Effect) Dry eye
Dry eye {u} (Side Effect) is caused by {v} (Compound) Trospium
Trospium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mirabegron
Ketoconazole {u} (Compound) resembles {v} (Compound) Itraconazole
Itraconazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Mirabegron
Ketoconazole (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Mirabegron (Compound)
Ketoconazole (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Mirabegron (Compound)
Ketoconazole (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Dexamethasone (Compound) and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Ketoconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Propafenone (Compound) and Propafenone (Compound) resembles Mirabegron (Compound)
Ketoconazole (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Propafenone (Compound) and Propafenone (Compound) resembles Mirabegron (Compound)
Ketoconazole (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Aprepitant (Compound) and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Ketoconazole (Compound) causes Arthralgia (Side Effect) and Arthralgia (Side Effect) is caused by Enzalutamide (Compound) and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Ketoconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Enzalutamide (Compound) and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Ketoconazole (Compound) causes Dry eye (Side Effect) and Dry eye (Side Effect) is caused by Trospium (Compound) and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron
Ketoconazole (Compound) resembles Itraconazole (Compound) and Itraconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Mirabegron (Compound)